- Home
- ACIU vs ENGN Comparison
ACIU vs ENGN Comparison
Compare ACIU & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIU | ENGN |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 379.3M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACIU | ENGN |
|---|---|---|
| Price | $3.14 | $8.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $10.00 | ★ $22.71 |
| AVG Volume (30 Days) | ★ 1.3M | 528.5K |
| Earning Date | 11-04-2025 | 12-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,482,957.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $738.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $2.65 |
| 52 Week High | $4.00 | $11.14 |
Technical Indicators
Market Signals| Indicator | ACIU | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 55.12 |
| Support Level | $2.54 | $7.77 |
| Resistance Level | $2.99 | $8.49 |
| Average True Range (ATR) | 0.29 | 0.61 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 50.40 | 66.45 |
Price Performance
Historical ComparisonAbout ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.